Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2018 16:24 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
May 14, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference

EMERYVILLE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
May 09, 2018 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports First Quarter Financial Results

Following receipt of Breakthrough Therapy Designation, conducted successful Type B meeting with FDA confirming adequacy of Phase 3 program for ZX008 NDA in Dravet syndromeStudy 1504 fully enrolled...
May 04, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9

EMERYVILLE, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
May 01, 2018 17:00 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
April 27, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome

ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo Data Presented During Emerging Therapies Plenary Session...
April 25, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

Efficacy and Safety Data in Patients on ZX008 Who Previously Failed Stiripentol Treatment Prior to Entry into First Phase 3 Trial (Study 1) Comparable to Results from Full Study 1 Population Patients...
April 11, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in LEERINK Partners CNS Day

EMERYVILLE, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
March 06, 2018 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

ZX008 Granted Breakthrough Therapy Designation in Dravet syndrome by FDALast patient randomized into second Phase 3 clinical trial of ZX008 in patients with Dravet syndrome, Study 1504Initiated global...
February 27, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6

EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...